<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03198689</url>
  </required_header>
  <id_info>
    <org_study_id>BV201708</org_study_id>
    <nct_id>NCT03198689</nct_id>
  </id_info>
  <brief_title>Brentuximab Vedotin in Early Diffuse Cutaneous Systemic Sclerosis</brief_title>
  <official_title>A Pilot Study of Adcetris Treatment in Active Diffuse Cutaneous Systemic Sclerosis (Diffuse Scleroderma)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lawson Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seattle Genetics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Lawson Health Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess feasibility, safety and preliminary efficacy of
      Brentuximab vedotin (Adcetris), a CD30-directed antibody-drug conjugate, in the treatment of
      active diffuse cutaneous systemic sclerosis (dcSSc).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Systemic sclerosis (SSc, Scleroderma) is a multisystem autoimmune disease characterized by
      widespread vascular injury and progressive fibrosis of the skin and internal organs. Internal
      organ involvement results in increased mortality of SSc patients. There is no effective
      treatment for the majority of patients with early active diffuse scleroderma (diffuse
      cutaneous systemic sclerosis; dcSSc). These patients early in their disease may be able to
      reverse their inflammation and reduce the probability of irreversible fibrosis via
      significant immune modulation. This is a pilot study that will treat 10 patients with early
      or active dcSSc who meet inclusion criteria to determine if the benefit of Brentuximab
      vedotin and safety are favorable in order to consider a randomized controlled trial. This is
      a Phase II study that is uncontrolled and patients will remain on their background immune
      suppressive treatment unless if contraindicated for safety or drug interactions. The trial is
      powered to show a mean change in mRSS of 8 over one year in an uncontrolled, unblinded study.
      The Health Assessment Questionnaire Disability Index (HAQ), patient and physician global
      scores, inflammatory markers (ESR, CRP), and combined response index in SSc (CRISS) will all
      be exploratory outcomes. Other outcomes such as changes in CD30-stained cells on skin
      biopsies with IHC from baseline to end of the trial will be explored if the study is
      positive.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2018</start_date>
  <completion_date type="Anticipated">June 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open Label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in skin thickness measured by modified Rodnan Skin Score (mRSS)</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in mRSS</measure>
    <time_frame>3, 6 and 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRISS score &gt;20%</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FVC, %</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in DLCO, %</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in physician-assessed disease activity, severity and damage on VASs ranked from 0 to 10</measure>
    <time_frame>3,6,9 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in patient global assessment of health status (VAS 0 to 10)</measure>
    <time_frame>3,6,9 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Health Transition score</measure>
    <time_frame>3,6,9 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SHAQ</measure>
    <time_frame>3,6,9 and 12 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in blood levels of soluble CD30</measure>
    <time_frame>3,6,9 and 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in serum levels of sIL-2R</measure>
    <time_frame>3,6,9 and 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in serum levels of aminoterminal propeptide of type III collagen</measure>
    <time_frame>3,6,9 and 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in myofibroblast score in skin biopsies of involved forearm skin</measure>
    <time_frame>6 and 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in CD30-positive cell count in skin biopsies of involved forearm skin</measure>
    <time_frame>6 and 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in erythrocyte sedimentation rate</measure>
    <time_frame>3,6,9 and 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in hsCRP levels</measure>
    <time_frame>3,6,9 and 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of patients with infectious complications</measure>
    <time_frame>up to 1 month post-treatment</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of patients with regimen-related toxicities</measure>
    <time_frame>up to 12 weeks post-treatment</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Diffuse Cutaneous Systemic Sclerosis</condition>
  <arm_group>
    <arm_group_label>Administration of Brentuximab vedotin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Maximum duration of treatment: 48 weeks Maximum dose allowed: 0.6 mg/kg Route of administration: intravenous use</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brentuximab Vedotin</intervention_name>
    <description>Dose 0.6 mg/kg i.v. will be given every 3 weeks for 16 cycles (48 weeks) in addition to standard of care medications for SSc that may include cyclophosphamide, methotrexate, azathioprine, mycophenylate mofetil (MMF, cellcept) and mycophenolic acid (myfortic).</description>
    <arm_group_label>Administration of Brentuximab vedotin</arm_group_label>
    <other_name>ADCETRIS, SGN-35</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18 years or older

          -  able to give informed consent

          -  meet the ACR/EULAR classification criteria for SSc

          -  early dcSSc (disease duration ≤ 5 years from first non-Raynaud's phenomenon symptom)
             OR active dcSSc as determined by worsening mRSS, presence of tendon friction rubs,
             and/or elevated inflammatory markers thought to be due to active dcSSc and not related
             to other issues

          -  mRSS≥ 15

          -  a negative TB skin test at screening, or treatment with INH for 6 months or other
             standardized LBTI (latent TB infection) treatment in the past

        Exclusion Criteria:

          1. Poor pulmonary function (FVC&lt;40% and/or DLCO&lt;30%).

          2. Pregnancy, breast feeding or child bearing potential without practicing reliable
             contraception (and partners for men in the study).

          3. Clinically significant pulmonary hypertension requiring drug therapy.

          4. Clinically significant cardiac disease.

          5. Chronic or ongoing active infectious disease requiring systemic treatment.

          6. Seropositivity for human immunodeficiency virus (HIV) at study entry.

          7. Active tuberculosis (TB) infection.

          8. Active viral infection with viral replication of hepatitis B or C virus at study
             entry.

          9. Significant concurrent, uncontrolled medical condition including, but not limited to,
             renal, hepatic, pancreatic, haematological, gastrointestinal, endocrine, pulmonary,
             neurological, cerebral or psychiatric disease; and cancer.

         10. Peripheral neuropathy at screening Grade 2 or higher.

         11. Known or suspected hypersensitivity to components of the treatment

         12. Patients known or suspected of not being able to comply with a study protocol (e.g.
             due to alcoholism, drug dependency or psychological disorder)

         13. Any of the following laboratory abnormalities at screening:

               -  Absolute neutrophils count &lt;2000/mm3

               -  Hemoglobin &lt;85 g/L

               -  Platelet count &lt; 100,000/mm3

               -  AST/SGOT or ALT/SGPT &gt;2.0 UNL

         14. Participation in another clinical trial within six weeks before randomization in this
             study

         15. Use of rituximab within the previous 4 months.

         16. Immunization with a live/ attenuated vaccine less than 4 weeks prior to the baseline
             visit.

         17. Previous use of brentuximab vedotin.

         18. Current or history of progressive multifocal leukoencephalopathy (PML).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janet E Pope</last_name>
    <role>Principal Investigator</role>
    <affiliation>1University of Western Ontario, Division of Rheumatology, St. Joseph's Health Care, London, Ontario, Canada</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Janet E Pope, MD PhD</last_name>
    <phone>519-646-6332</phone>
    <email>janet.pope@sjhc.london.on.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Louise Vanderhoek</last_name>
    <phone>519-646-6000</phone>
    <phone_ext>61022</phone_ext>
    <email>Louise.Vanderhoek@sjhc.london.on.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rheumatology Clinic, St. Joseph's Health Care</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4V2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Janet E Pope</last_name>
      <phone>519-646-6332</phone>
      <email>janet.pope@sjhc.london.on.ca</email>
    </contact>
    <investigator>
      <last_name>Janet E Pope</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tatiana Nevskaya</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Louise Vanderhoek</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sara Hewitt</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Young A, Khanna D. Systemic sclerosis: a systematic review on therapeutic management from 2011 to 2014. Curr Opin Rheumatol. 2015 May;27(3):241-8. doi: 10.1097/BOR.0000000000000172. Review.</citation>
    <PMID>25775190</PMID>
  </reference>
  <reference>
    <citation>Shah AA, Casciola-Rosen L, Rosen A. Review: cancer-induced autoimmunity in the rheumatic diseases. Arthritis Rheumatol. 2015 Feb;67(2):317-26. doi: 10.1002/art.38928. Review.</citation>
    <PMID>25371098</PMID>
  </reference>
  <reference>
    <citation>Pope JE, Baron M, Bellamy N, Campbell J, Carette S, Chalmers I, Dales P, Hanly J, Kaminska EA, Lee P, et al. Variability of skin scores and clinical measurements in scleroderma. J Rheumatol. 1995 Jul;22(7):1271-6.</citation>
    <PMID>7562757</PMID>
  </reference>
  <reference>
    <citation>Furst DE, Khanna D, Mattucci-Cerinic M, Silman AJ, Merkel PA, Foeldvari I; OMERACT 7 Special Interest Group. Scleroderma--developing measures of response. J Rheumatol. 2005 Dec;32(12):2477-80.</citation>
    <PMID>16331791</PMID>
  </reference>
  <reference>
    <citation>Pope JE, Bellamy N. Outcome measurement in scleroderma clinical trials. Semin Arthritis Rheum. 1993 Aug;23(1):22-33. Review.</citation>
    <PMID>8235663</PMID>
  </reference>
  <reference>
    <citation>Sutherland MS, Sanderson RJ, Gordon KA, Andreyka J, Cerveny CG, Yu C, Lewis TS, Meyer DL, Zabinski RF, Doronina SO, Senter PD, Law CL, Wahl AF. Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. J Biol Chem. 2006 Apr 14;281(15):10540-7. Epub 2006 Feb 16.</citation>
    <PMID>16484228</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2017</study_first_submitted>
  <study_first_submitted_qc>June 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2017</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lawson Health Research Institute</investigator_affiliation>
    <investigator_full_name>Janet Pope</investigator_full_name>
    <investigator_title>Head of Rheumatology</investigator_title>
  </responsible_party>
  <keyword>systemic sclerosis</keyword>
  <keyword>scleroderma</keyword>
  <keyword>brentuximab vedotin</keyword>
  <keyword>CD30-directed antibody-drug conjugate</keyword>
  <keyword>antirheumatic agents</keyword>
  <keyword>antineoplastic agents</keyword>
  <keyword>connective tissue diseases</keyword>
  <keyword>skin diseases</keyword>
  <keyword>immunologic factors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

